{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:12:15Z","timestamp":1791727935630,"version":"4.3.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To study the effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on glucose metabolism and abdominal fat distribution in patients with obesity and type 2 diabetes mellitus (T2DM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From April 30, 2020, to April 30, 2022, a prospective randomized controlled study was carried out at the Endocrinology Department of Beijing Hospital, the National Center of Gerontology. According to the in- and exclusion criteria and by the random table method, revisited T2DM patients were selected as the research subjects and were allocated into a Study group (taking liraglutide) and a Control group (underwent lifestyle interventions). All patients received continuous 12-weeks interventions to the endpoint, and the changes of value [\u0394=(endpoint)-(baseline)] of physical measurements, blood tests, the energy spectrum CT examination results, and body composition analysis results were analyzed and compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 85 people completed this study, and among them, 47 were in the Study group and 38 were in the Control group. Compared with the Control group, the changes of hemoglobin A1c (HbA1c) level (-0.78 \u00b1 1.03% vs. -1.57 \u00b1 2.00%, <jats:italic>P<\/jats:italic>=0.025), visceral fat area (0.91 \u00b1 16.59 cm<jats:sup>2<\/jats:sup> vs. -7.1 \u00b1 10.17 cm<jats:sup>2<\/jats:sup>, <jats:italic>P<\/jats:italic>=0.011), and subcutaneous fat area of abdomen [0 (-18.75, 15.5) cm<jats:sup>2<\/jats:sup> vs. -16.5 (-41.75, -2.25) cm<jats:sup>2<\/jats:sup>, <jats:italic>P<\/jats:italic>=0.014] were all greater in the Study group. The adverse events caused by liraglutide were mainly concentrated in the gastrointestinal system and all of them were minor adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Liraglutide can be the drug of choice for weight management and reduction of abdominal fat distribution in patients with obesity and T2DM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.951570","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T05:53:10Z","timestamp":1661493190000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study"],"prefix":"10.3389","volume":"13","author":[{"given":"Dongni","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Practice Ireland"},{"key":"B2","doi-asserted-by":"publisher","first-page":"154910","DOI":"10.1016\/j.metabol.2021.154910","article-title":"Heart failure in diabetes","volume":"125","author":"Jankauskas","year":"2021","journal-title":"Metabol: Clin Exp"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13197","article-title":"Trends in diabetes and obesity in Samoa over 35 years, 1978-2013","volume":"34","author":"Lin","year":"2017","journal-title":"Diabetic medicine : J Br Diabetic Assoc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12933-020-01095-4","article-title":"Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference","volume":"19","author":"Wan","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000000485","article-title":"How to best assess abdominal obesity","volume":"21","author":"Fang","year":"2018","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S009","article-title":"9. pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care United States"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.52.8961","article-title":"Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus","volume":"52","author":"Suzuki","year":"2013","journal-title":"Internal Med (Tokyo Japan) Japan"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002","article-title":"2. classification and diagnosis of diabetes: Standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care United States"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0589","article-title":"Effects of liraglutide on weight loss, fat distribution, and \u03b2-cell function in obese subjects with prediabetes or early type 2 diabetes","volume":"40","author":"Santilli","year":"2017","journal-title":"Diabetes Care United States"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3042","article-title":"Obesity and diabetes-not only a simple link between two epidemics","volume":"34","author":"Chobot","year":"2018","journal-title":"Diabetes\/Metabolism Res Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9","year":"2020","journal-title":"Circ Research United States"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/pedi.12787","article-title":"Does obesity cause type 2 diabetes mellitus (T2DM)? or is it the opposite","volume":"20","author":"Malone","year":"2019","journal-title":"Pediatr diabetes Denmark"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1519\/JSC.0b013e3181fb4a46","article-title":"The effect of abdominal exercise on abdominal fat","volume":"25","author":"Vispute","year":"2011","journal-title":"J Strength Conditioning Research United States"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2021.01.031","article-title":"Improvement of glucose metabolism following rapid weight loss after bariatric surgery and its impact on reduction of visceral abdominal fat versus free fat muscle","volume":"17","author":"Cogollo","year":"2021","journal-title":"Surg Obes Related Dis: Off J Am Soc Bariatric Surgery United States"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.9b00048","article-title":"Inventing liraglutide, a glucagon-like peptide-1 analogue, for the treatment of diabetes and obesity","volume":"2","author":"Knudsen","year":"2019","journal-title":"ACS Pharmacol Trans Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: Efficacy in fat loss and safety in order to prevent sarcopenia. a perspective case series study","volume":"28","author":"Perna","year":"2016","journal-title":"Aging Clin Exp Research Germany"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S97383","article-title":"Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus","volume":"10","author":"Rondanelli","year":"2016","journal-title":"Patient Preference Adherence"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57070669","article-title":"A 2021 update on the use of liraglutide in the modern treatment of \u300aDiabesity\u300b: A narrative review","volume":"57","author":"Tilinca","year":"2021","journal-title":"Med (Kaunas Lithuania)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-18-0374","article-title":"The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution","volume":"240","author":"Zhao","year":"2019","journal-title":"J endocrinol Engl"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2013.1350","article-title":"Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes","volume":"31","author":"Yang","year":"2013","journal-title":"Int J Mol med Greece"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12634","article-title":"Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1\/SIRT3-FOXO3a pathway","volume":"46","author":"Tong","year":"2016","journal-title":"Hepatol research : Off J Japan Soc Hepatol Netherlands"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00432","article-title":"Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.12.149","article-title":"Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway","volume":"510","author":"Li","year":"2019","journal-title":"Biochem Biophys Res Communications United States"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13008","article-title":"Cooperative role of the glucagon-like peptide-1 receptor and \u03b23-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA\/AKT\/AMPK signalling in the adipose tissue and muscle of rats","volume":"222","author":"Decara","year":"2018","journal-title":"Acta Physiologica (Oxford England) Engl"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000360","article-title":"Current body composition measurement techniques","volume":"24","author":"Lemos","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-07820-1","article-title":"Skeletal muscle fat quantification by dual-energy computed tomography in comparison with 3T MR imaging","volume":"31","author":"Molwitz","year":"2021","journal-title":"Eur Radiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3647","article-title":"Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: A prospective case series","volume":"11","author":"Ishii","year":"2019","journal-title":"J Clin Med Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.951570\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T05:53:13Z","timestamp":1661493193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.951570\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":27,"alternative-id":["10.3389\/fendo.2022.951570"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.951570","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"article-number":"951570"}}